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Background/aim: CHARGE syndrome is a rare autosomal dominant disease with multiple congenital anomalies and cognitive
impairment, which is caused by mutations in the CHD7 gene. This study aimed to disclose the mild end of the phenotypic spectrum of
CHARGE syndrome, which has a highly variable expressivity.
Materials and methods: Twenty-one patients who had at least one of the major symptoms of CHARGE syndrome (coloboma, choanal
atresia, characteristic ear anomalies, semicircular canal hypoplasia, and cranial nerve anomalies) were included in the study. All patients
were tested for karyotype analysis and CHD7 gene mutation/deletion.
Results: In the study population, 6 different mutations were detected in 5 patients, and 2 different polymorphisms were detected in the
CHD7 gene in 3 patients. MLPA analysis of all coding exons of the CHD7 gene revealed no pathogenic deletion/duplication.
Conclusion: CHARGE syndrome should be considered as a differential diagnosis to detect the mild end of the spectrum, even if the
patient does not fit the criteria.
Key words: Choanal atresia, coloboma, CHD7 gene, semicircular canal hypoplasia

1. Introduction
CHARGE syndrome (Hall–Hittner syndrome; OMIM
#214800) is a rare (incidence ranges between 1/8500
and 1/12,000) autosomal dominant disorder, which is
characterized by ocular coloboma, heart defects, atresia of
the choanae, retardation of growth, genital hypoplasia, and
ear malformations. In addition, involvement of multiple
systems is reported. Considering that these symptoms
point to various other syndromes, the Blake and Verloes
criteria were developed to facilitate differential diagnosis
(1–4). Although a great number of patients are initially
considered to have typical CHARGE syndrome according
to these criteria, some of them receive a different diagnosis
later during follow-up (2).
Chromodomain helicase DNA binding protein 7
(CHD7) gene mutations are found in at least 48% of
patients with CHARGE syndrome. This rate rises to 90%
in patients who are diagnosed with a typical presentation
of CHARGE syndrome according to Blake and/or Verloes
criteria (3). In addition, many patients with mutations
of this gene exhibit a wide range of variable expressivity.
For instance, CHD7 gene mutations have been detected

in patients who have only external ear and/or cardiac
defects (5). The mild end of the phenotypic spectrum of
CHD7 mutations needs more clarification. In this case, if
only patients complying with Blake and/or Verloes criteria
are evaluated, a considerable portion of the patients
(approximately 20%) will be underestimated (3).
In light of these findings, we evaluated all patients who
had at least one major criterion and were suspected to
have CHARGE syndrome during an initial examination.
We discuss the clinical symptoms of all patients, with
and without mutations, along with other syndromes
considered in differential diagnosis.
2. Materials and methods
2.1. Patients
A total of 21 patients with preliminary diagnosis of CHARGE
syndrome were included in the study, who were examined
at the Department of Pediatric Genetics and Department
of Medical Genetics between June 2014 and July 2015.
They had at least one of the major symptoms (coloboma,
choanal atresia, characteristic ear anomalies, semicircular
canal hypoplasia, and cranial nerve anomalies). Medical
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history, physical examination findings and anthropometric
measurements, and preliminary diagnoses that were
considered during initial examination were also recorded.
All patients were screened for possible anomalies
associated with CHARGE syndrome. All patients were
tested for CHD7 gene mutations/deletions. The parents of
the patients were also screened for the CHD7 gene in cases
that had mutation/polymorphism of the gene.
The control group involved healthy age-matched
children without any dysmorphic findings. Informed
consent was obtained from all families in the study and
control groups.
2.2. Methods
2.2.1. Karyotype analysis
Chromosome preparations were obtained from
lymphocyte cultures and G banding was performed to
identify individual chromosomes. Karyotyping was done
according to guidelines of the International System for
Human Cytogenetic Nomenclature.
2.2.2. Sanger sequencing and MLPA analysis
Genomic DNA from the peripheral blood lymphocytes
of all individuals was extracted with the QIAamp
DNA Blood Mini Kit (QIAGEN GMBH, Hilden,
Germany) using standard procedures. All coding exons
and exon-intron boundaries of the CHD7 gene were
amplified by polymerase chain reaction (PCR) using
HelixAmp Ready-2X-Multiplex version 2.0 PCR mix
(NanoHelix). The sequences were evaluated using the
CLC Genomics Workbench 3 sequencing program
(QIAGEN). The “Ensembl.org” database (GRCh38.p3,
GCA_000001405.18) with ENST00000423902 transcript
ID of the CHD7 gene was used for comparing the
individual’s sequence and the reference sequence. All
variations were checked from mutation and SNP databases
(Human Genome Mutation Database - HGMD, National
Center for Biotechnology Information - NCBI/SNP,
ensembl.org, chd7.org). Each variation was confirmed
by bidirectional sequencing. Variation descriptions were
done according to the nomenclature recommended by the
Human Genomic Variation Society. Novel variations were
screened in the control group. The control group consisted
of 106 individuals who were admitted to our hospital
for routine outpatient evaluation. None of them had a
history of chronic systemic disease or genetic disorders.
Furthermore, in silico programs, such as SIFT, PolyPhen
2, Mutation Taster, and KD4V, were used to describe the
pathogenicity of novel variations in coding exons and
exon-intron boundaries.
Multiplex ligation-dependent probe amplification
(MLPA) analyses were performed to detect large deletions
and duplications using the P201 SALSA MLPA Kit (MRCHolland, the Netherlands). The PCR products were
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analyzed by ABI 3130 capillary electrophoresis system
and Coffalyser software. Differences of the peak areas
between the individual’s sample and control samples were
evaluated.
3. Results
Twenty-one patients were included in the study. Coloboma
was the major presenting symptom in 11 patients, whereas
choanal atresia was recorded in 13 patients, hypoplastic
semicircular canals in 3 patients, and cranial nerve
dysfunction in 8 patients.
In the study group, 6 different mutations were
detected in 5 patients (Figures 1a–1e), and 2 different
polymorphisms were detected in the CHD7 gene in
3 patients. Three of 6 different mutations were novel.
The patient who had coloboma, choanal atresia, and
sensorineural deafness had two novel mutations in
adjacent nucleotides in exon 2, c.1281 T>G and c.1282
C>G, which were affecting adjacent codons and resulting
in two amino acid changes: (p.Y427X) and (p.P428A).
The other novel frameshift mutation, c.4103_4104insGC
(p.G3169Qfs*4), was detected in a patient who had
choanal atresia, bilateral semicircular hypoplasia, and
mixed type hearing loss. These novel mutations were not
found in any parents or in 106 ethnically matched control
individuals. MLPA analysis of all coding exons of the
CHD7 gene revealed no pathogenic deletion/duplication
in the study group. Karyotype analysis of the patients was
also normal.
One of the patients with a CHD7 mutation was
diagnosed with typical CHARGE syndrome according
to the Blake criteria. On the other hand, 3 patients had
symptoms consistent with typical CHARGE syndrome
and 2 patients had symptoms consistent with atypical
CHARGE syndrome according to the Verloes criteria.
The clinical findings, mutation profiles, and potential
differential diagnoses are summarized in the Table.
CHD7 mutations were not detected in 16 patients; 4
(25%) of these patients had findings consistent with typical
CHARGE syndrome according to the Blake criteria. On
the other hand, according to the Verloes criteria, only 3
(18%) of these patients had typical CHARGE findings.
Accordingly, VACTERL (5/21) and VCFS (8/21) were the
most likely differential diagnoses in cases with no mutation.
Analysis of the 22q11 region did not show deletion in any
of the patients. Two of the patients received the diagnosis
of Ritscher–Schinzel syndrome and acromelic frontonasal
dysostosis later during follow-up.
4. Discussion
Mutations in the CHD7 gene, encoding chromodomain
helicase DNA-binding protein, have been identified in
48%–90% of affected individuals (2). In the present study,
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Figure 1. Sequence analysis of mutation-positive cases: patient 1
(a), patient 2 (b), patient 3 (c), patient 4 (d), patient 5 (e).

this rate was approximately 24%. It is difficult to generalize
the findings due to the small sample size, which consisted
of patients with a single major symptom. In addition,

our results show that performing a mutation screening
only in patients who comply with criteria would result
in underestimation of approximately 20% of the patients
if evaluated by the Blake criteria. However, only 3 of 5
patients with mutations had typical CHARGE syndrome
features according to the Verloes criteria, whereas only 1 of
5 patients had typical CHARGE syndrome characteristics
according to the Blake criteria.
Coloboma is a major symptom of CHARGE
syndrome. Unilateral or bilateral coloboma with/without
microphthalmia have been reported in 65%–75% of
individuals with CHARGE syndrome (4). In our cohort
the incidence was 58% (11/19) among all patients and 40%
(2/5) in cases with mutation. Another finding, choanal
atresia or stenosis, has been reported in 50%–60% of
CHARGE syndrome cases (2). As a major abnormality
choanal atresia has been noted in 72% (13/18) of our
patients. When cases with mutations are taken into
consideration, this abnormality has been noted in 80%
(4/5) of our patients.
Ear anomalies have been reported in 80%–100%
of patients with CHARGE syndrome. Most include
external ear anomalies (lop or cup-shaped, low set with
decreased vertical height) (2). In the current study, 10 of
the mutation-negative cases and 4 of 5 mutation-positive
cases had external ear malformations. Furthermore,
mixed, conductive, or sensory causes of hearing loss have
been reported in 86%–89% of patients with CHARGE
syndrome. Audiogram/ABR should be included in routine
examinations (1,4,6). Among our patients who had
deafness, sensorineural and mixed type hearing deficiencies
were detected in 5 and 6 patients, respectively. Of cases
with mutations, the 1st and 3rd cases had sensorineural
and mixed type hearing deficiency, respectively.
Semicircular canal defects, which are accepted as major
signs, may be considered as inner ear abnormalities, and
they are seen in as many as 95% of patients with CHARGE
syndrome (7). Computed tomography (CT) examination is
required to confirm semicircular canal hypoplasia/aplasia,
cochlear hypoplasia, and Mondini defect (decreased
number turns of cochlea). On the other hand, most
centers, including ours, do not use CT as part of the initial
screening, unless other indications are present. Some
patients require cochlear implants. In such cases, MRI
examination is recommended to rule out aberrant facial
nerve (8–11). Only one of our cases with CHD7 mutation
had semicircular canal hypoplasia. This malformation was
not detected in mutation-negative cases, but abnormalities
of semicircular canals were detected in two patients.
Involvements of cranial nerves (I, II, V, especially VII
and VIII, and IX, X, and XI) are commonly observed in
CHARGE syndrome, which are usually asymmetric (1,2).
In our patients with CHD7 mutations, one had facial
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CHARGE syndrome
Apert syndrome
Velocardiofacial syndrome (VCFS)

CHARGE syndrome
Velocardiofacial syndrome (VCFS)

Warburg Micro syndrome
CHARGE syndrome

Delayed psychomotor
development
Mild hypotonia
Epicanthus
Bilateral posterior embryotoxon
Flat nasal bridge
Cardiovascular malformation
(aberrant supraclavicular artery)

Retrognathia
Depressed nasal bridge
Cleft palate
Cardiovascular malformation
Mild mental retardation
Microphthalmia
Microcornea
Retinal detachment
Cardiovascular malformation
Renal hypoplasia
Hypogonadotropic
hypogonadism

Choanal atresia
Small-curled low-set ears
Bilateral semicircular hypoplasia
Hearing loss (mixed type)

Choanal atresia
Cup-shaped malformed ears
Facial paralysis
Hearing loss (mixed type)

Coloboma
Choanal atresia

Low-set, cup-shaped ears
Optic disc hypoplasia
Hearing loss (mixed type)

1

2

3

4

5

CHARGE syndrome
Velocardiofacial syndrome (VCFS)
Floating harbor S
Moebius syndrome
Teratogen exposure (methimazole)

CHARGE syndrome
Fryns–microphthalmia syndrome
Cat-eye syndrome

Square face
Microphthalmia
Micrognathia
Cardiovascular malformation

Coloboma (optic disc, retina, and choroid)
Choanal atresia
Posteriorly rotated, cup-shaped ears
Sensorineural deafness

Triangular face
Low hairline and bilateral simian
crease
Cardiovascular malformation

Differential diagnosis of the patients

Minor signs**

Major signs*

Patient no.

Table. Clinical findings and differential diagnosis options of mutation-positive cases.

c.8962dupG (D2988fs)

c.3005A>G (Q1002R)

c.2954_56del (ACAdel)

c.4103_4104insGC (p.G3169Qfs*4)

c.1282 C>G (p.P428A)

c.1281 T>G (p.Y427X)

Mutations
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paralysis and 4 had sensorineural or mixed type hearing
loss. Absence or anomalies of cranial nerve I causes
anosmia. Pathologies of the eighth nerve appear as neural
or combined deafness; involvement of nerves IX, X, and XI
appear as swallowing/feeding difficulties (80%) (2).
Besides CHARGE syndrome, 18 different clinical cases
associated with CHD7 mutations are described in the
Human Gene Mutation Database. These include isolated
temporal bone malformation, autism, hypogonadotropic
hypogonadism, Kallmann syndrome, and isolated mental
retardation
(http://www.hgmd.cf.ac.uk/ac/index.php).
Furthermore, the identification of novel CHD7 mutations
with various phenotypes in CHARGE patients will improve
the clinical practice and genotype/phenotype correlations.
In this study CHD7 gene analysis was performed for
21 patients, which led to the identification of six CHD7

alterations. These included 1 deletion, 3 point mutations,
1 duplication, 1 insertion, and a splice site mutation in 5
patients. Double mutation was present in one patient. The
mild end of the phenotypic spectrum of CHD7 mutations
needed to be clearly defined. Therefore, all patients with
suspicion of CHARGE syndrome, even if only one major
symptom was present, were evaluated.
In conclusion, the analysis of CHD7 gene mutation/
deletion in our patients with at least one major criterion
is not sufficient to disclose the mild end of the spectrum
of CHARGE syndrome. On the other hand, CHARGE
syndrome should be considered as a differential diagnosis
in the case of clinical suspicion even if the patient does not
fit the Blake criteria. This is necessary in order to not miss
the mild end of the spectrum.
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